Medroxyprogesterone Acetate
Medroxyprogesterone acetate (INN, USAN, BAN), also known as 17α-hydroxy-6α-methylprogesterone acetate, and commonly abbreviated as MPA, is a steroidal progestin, a synthetic variant of the steroid hormone progesterone.[2][3] It is used as a contraceptive, in hormone replacement therapy and for the treatment of endometriosis as well as several other indications.
Starting at
Product Description
| 17α-hydroxy-6α-methylpregn-4-ene-3,20-dione acetate |
| Trade names | Depo-Provera (injection), Provera (oral) |
| AHFS/Drugs.com | FDA Professional Drug Information |
| MedlinePlus | a604039 |
| Pregnancy category |
US: X (Contraindicated) |
| Legal status | ℞ (Prescription only) |
| Routes of administration |
Oral, IM |
| Bioavailability | 99%[1] |
| Protein binding | 88% (to albumin)[1] |
| Biological half-life | 40-60 hours |
| CAS Number | 71-58-9 |
| ATC code | G03AC06 G03DA02, L02AB02 |
| PubChem | CID: 6279 |
| IUPHAR/BPS | 2879 |
| DrugBank | DB00603 |
| ChemSpider | 6043 |
| UNII | C2QI4IOI2G |
| KEGG | C08150 |
| ChEBI | CHEBI:6716 |
| ChEMBL | CHEMBL717 |
| Formula | C24H34O4 |
| Molecular mass | 386.52 g/mol |
